Artemis Medicare: the case for buying the blueprint before the building is finished.

2026-05-28 · 7 min read · Markets · CMP ₹270

There is a specific moment in the life of a business that most investors find deeply uncomfortable. The numbers are getting worse. Management is spending money aggressively. Near-term earnings visibility is low. And yet, if you stand back and look at what is actually being built, the future is substantially brighter than the present suggests.

Artemis Medicare is in that moment right now.

The Gurugram hospital, their single operating asset today, is one of the finest tertiary care facilities in the country. ARPOB of Rs. 84,571 per bed is top-tier. International patients make up 32% of revenue, which tells you the clinical reputation reaches well beyond Delhi-NCR. Eight consecutive quarters of year-on-year profit growth. EBITDA margins at 20.2% for the full year. Net cash on the balance sheet. Interest coverage at 8.1 times. This is not a struggling business. This is a business that has mastered its first chapter.

The problem the market has with Artemis is not the Gurugram hospital. The problem is everything Artemis is building next.

The market prices what it can see. It discounts, sometimes severely, what is being built but not yet visible in earnings.

The Raipur hospital opened this quarter and will lose Rs. 18-20 crore annually for the next two to three years as it finds its patient base, builds its referral network, and reaches operating maturity. The VIMHANS South Delhi O&M agreement commits Rs. 500-520 crore over the coming years for a 650-bed quaternary care facility that does not open Phase 1 until FY29. A Rs. 700 crore QIP is planned to fund it all, which will dilute earnings per share by roughly 15% in the near term.

Put all of that together and Q1 FY27 results, out in August, will look worse than Q4 FY26 on a per-share basis. That is almost certain. Management disclosed the Raipur drag openly and specifically on their May 11 earnings call, which is itself worth noting. They told you exactly what is coming and they recommended a dividend anyway. That combination, full transparency about near-term pain alongside confidence in long-term returns, is not the behaviour of a management team navigating a deteriorating business.

Beds: FY26 → FY29

700 → 1,700

2.4x expansion

PAT CAGR FY25-28E

31%

Choice Broking est.

PEG ratio

1.07x

Sector trades at 2-4x

The mental model I keep returning to with Artemis is this. The valuation of a platform business should not be anchored to what it earns today. It should be anchored to what the platform will earn when its constituent assets have matured. Raipur at year three will look nothing like Raipur at year one. South Delhi, when it opens, plugs Artemis into a catchment area with no comparable private quaternary care provider. The Gurugram flagship, with 100 additional beds coming at near-zero incremental land cost from a Green Building Certification, will generate almost pure incremental margin on those beds.

The hospital chains that command the highest multiples in India (Apollo, KIMS, Aster, Narayana) do not trade at those multiples because they run one hospital exceptionally well. They trade there because the market values the platform: multiple assets, diversified geographies, shared procurement, brand spillover. Single-asset hospitals are permanently discounted relative to that. Artemis is in the process of escaping that discount by building what the market rewards.

What the IFC is telling you The International Finance Corporation, the private sector arm of the World Bank, has Rs. 330 crore in CCD funding in Artemis. The IFC does not make speculative healthcare bets. Their diligence process runs deep into clinical operations, management quality, governance, and expansion feasibility. They were in before the market took notice. Their continued involvement through the QIP process, which they are expected to participate in, is the highest-quality external validation available.

The risk I will not minimise is execution. A hospital network expanding from one city to three simultaneously, while managing a QIP, while absorbing the transition costs of two new assets, is not a simple undertaking. The promoter pledge situation deserves monitoring. And the Apollo Tyres group's core business in tyres is entirely separate from healthcare. Their commitment to the hospital, while consistent, is not their primary strategic focus.

These are real concerns. The way I think about sizing around them is straightforward. Artemis is not a position you take because you believe everything will go perfectly. It is a position you take because the downside (a net cash, IFC-backed, AA+ rated Gurugram hospital with a 31% PAT CAGR trajectory) is not as bad as the current price implies, and the upside from a successful platform transition is substantially larger than the current price reflects.

The discomfort of the investment phase is temporary. The value of the platform, if it gets built, is not.

The August Q1 FY27 result will test your conviction. Plan for it before it arrives, not after. If you understand what you own and why you own it, that print is not a reason to sell. It is potentially a better entry. If you do not understand it going in, that print will look like a deteriorating story and you will exit at the wrong price.

Understanding what you own is the only edge that compounds.

Platform transition Investment phase IFC backed Management transparency Forward PE 28x

CMP ~₹270. ICICI Direct conviction TP ₹340. Choice Broking TP ₹325. Analyst consensus ₹332.50. Not investment advice.